LobbyingHorizon Therapeutics USA lobbying by quarter
Horizon Therapeutics USA's latest lobbying report covers Q4 2023, at $60K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Horizon Therapeutics USA
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $60K | 1 |
| Q1 2023 | $60K | 1 |
| Q2 2023 | $60K | 1 |
| Q3 2023 | $60K | 1 |
| Q4 2023 | $60K | 1 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$120K · 4 reports
- Medicare and Medicaid$120K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
Firms it paid
| Firm | ||
|---|---|---|
| The McManus Group | $300K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ALANNA TEMME | LD, Rep. Jon Porter | Q3 2023 |
| JOHN MCMANUS | Staff Director W&M; LA, Rep. Bill Thomas | Q3 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/01/20for Q4 2023 | The McManus Group | $60K |
| 23/10/20for Q3 2023 | The McManus Group | $60K |
| 23/07/20for Q2 2023 | The McManus Group | $60K |
| 23/04/20for Q1 2023 | The McManus Group | $60K |
| 23/01/20for Q4 2022 | The McManus Group | $60K |